Pharmaceuticals & Medical Devices

Pharmaceuticals & Medical Devices

We shape law and practice covering pharmaceuticals and medical devices

With a full service practice, we leverage our expertise in the key areas of law that affect our pharmaceutical and medical device clients. By integrating intellectual property, commerce and technology expertise with our competition and regulatory experience, we enable you to both maximise opportunities and manage your business challenges.

Our legal advice assists at all stages of the product life cycle – from the laboratory to the household and beyond. And clients rely on our law firm for critical commercial and regulatory guidance.

We advise pharmaceutical companies (both originators and generics), biotechnology companies, research and development companies and medical devices manufacturers on:

  • Patent, Supplementary Protection Certificate and other intellectual property litigation
  • Regulatory law
  • Competition and anti-trust issues
  • Licensing and commercial exploitation
  • Commercial dispute resolution (including product liability, competition litigation and regulatory litigation)
  • Marketing and advertising issues
  • Brand clearance, protection, exploitation and enforcement
  • Corporate advice (including fund formation, capital raising, corporate structures, joint ventures, tax, mergers and acquisitions, takeovers and de-mergers)
  • Finance, advising both lenders and borrowers.

Show moreShow less

Our law firm’s experience in pharmaceuticals and medical devices includes advising:

  • Varian Medical Systems in relation to the negotiation of a Government Information Technology Contracting (GITC) agreement for the supply and support of complex IT systems
  • Telstra on the regulatory aspects of developing its High Definition TeleHealth Care
  • Colgate-Palmolive on registering Colgate Sensitive Pro-Relief (CSPR) as a medical device, through negotiations with the Australian Government’s Therapeutic Goods Administration (TGA)
  • Alphapharm and Watson Pharmaceuticals in patent litigation matters
  • Aspen Pharmacare in the Permax class action
  • Pfizer on a US$50 million divestment of its animal vaccine business to Harbin Pharmaceuticals
  • Shanghai Pharmaceuticals Holding Lists on the Hong Kong Stock Exchange
  • A major international pharmaceutical company on the clearance and adoption of its new over-the-counter (OTC) branding
  • Watson Pharmaceuticals on the acquisition of Belgium-based development company Uteron Pharma for US$150 million in cash up-front, and up to US$155 million in potential future milestone payments
  • Pharmaceutical companies in all of the leading investigations by the European Commission and UK Office of Fair Trading relating to alleged anti-competitive practices and originator / generic patent settlement agreements for perindopril, citalopram and paroxetine.
"Powerhouse for life sciences matters in core areas including corporate and commercial deals, patent litigation and regulatory affairs."

PLC

See our Life Sciences & Healthcare Update and Alert for the latest news and insights across the EU.

Your key contacts

We have a full team specialising in this area.

Discover our latest insights into legal issues affecting your business

A bipartisan group of senators has introduced another bill to aid the US semiconductor industry. The move signals continuing support across party lines for this important part of the US high...

03 July 2020

General 1. Administrative Measures on Strategic Investment in Listed Companies by Foreign Investors (Draft) On 18 June 2020, the Ministry of Commerce of the People’s Republic of China (MOFCOM...

01 July 2020

CFIUS has cleared a greenfield wind farm project in Texas, to be built by GH America Energy, a subsidiary of Shanghai-listed Guanghui Energy Co., Ltd. The project is in Val Verde County, along the...

29 June 2020

CFIUS cleared another China acquisition. The clearance came in late February but was only publicly announced by the NYSE-listed buyer in its recent SEC filing. The deal involves the acquisition of...

17 June 2020

This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

For more information on which cookies we use then please refer to our Cookie Policy.